PDCD1 and cancer: This study evaluated the safety, tolerability, pharmacokinetics, and initial efficacy of JS002 (Ongericimab), a bioengineered humanized anti-PCSK9 monoclonal antibody, combined with JS001 (Toripalimab), a PD-1 inhibitor, in individuals with progressive cancer for whom standard therapy has failed.